### 2024 Current Fiscal Year Report: Malaria Vaccine Development Program Scientific Advisory Committee

Report Run Date: 04/26/2024 02:22:36 AM

1. Department or Agency			2. Fiscal Year
Agency for International Development			2024
3. Committee or Subcommittee			3b. GSA Committee No.
Malaria Vaccine Development Program Scientific Advisory Committee			1056
4. Is this New D	uring 5. Current	6. Expected	7. Expected
Fiscal Year?	Charter	Renewal Date	Term Date
Yes			
8a. Was Termin FiscalYear?	ated During Terr	Specific nination nority	8c. Actual Term Date
No			
9. Agency Recommendati FiscalYear	on for Next	Legislation to Terminate?	10b. Legislation Pending?
Continue	No		
11. Establishme	ent Authority Ag	ency Authority	
12. Specific Establishment Authority	13. Effectiv Date	14. ve Commitee Type	14c. Presidential?
AGEN	08/06/1	997 Continuing	No
Advisory Board 16a. Total Number of Reports 17a.			her Activities 0 17d. Total 0

**Current Next** 

	FY	FY
18a(1). Personnel Pmts to	\$0.0	00\$0.00
Non-Federal Members		
18a(2). Personnel Pmts to	\$0.00 \$0.00	
Federal Members	<i><b>Q</b></i> 0.00 <i>Q</i> 0.00	
18a(3). Personnel Pmts to	\$0 (	00\$0.00
Federal Staff	ψ0.00 ψ0.00	σφο.σσ
18a(4). Personnel Pmts to	\$0.00\$0.00	
Non-Member Consultants		
18b(1). Travel and Per Diem to	\$0.0	00\$0.00
Non-Federal Members		
18b(2). Travel and Per Diem to	\$0.0	00\$0.00
Federal Members	φ0.00 φ0.00	
18b(3). Travel and Per Diem to	\$0 (	00\$0.00
Federal Staff	φ0.00 φ0.00	
18b(4). Travel and Per Diem to	\$0 (	00\$0.00
Non-member Consultants	n-member Consultants	
18c. Other(rents,user charges,	\$0 (	00\$0.00
graphics, printing, mail, etc.)	φ0.00 φ0.00	
18d. Total	\$0.0	00\$0.00
19. Federal Staff Support Years	0.0	00.0 00
(FTE)		

# 20a. How does the Committee accomplish its purpose?

The committee reviews malaria vaccine development progress and plans on a semi-annual or annual basis. Following an extensive review of data and progress presented by MVDP staff or collaborators, the committee deliberates and makes recommendations on specific approaches to malaria vaccine development, which are then incorporated into the plans as appropriate.

## 20b. How does the Committee balance its membership?

The committee includes members with experience in industry and academia, and with expertise in vaccine development, malariology, immunology, molecular biology, and clinical evaluation of vaccines. Both broad and specific technical advice is therefore available.

### 20c. How frequent and relevant are the Committee Meetings?

The meetings are held semi-annually or annually to provide the necessary oversight to ensure the continuing appropriate conduct of the program. The MVDP staff sets the agenda in consultation with the committee chairman and members and invites collaborators to present recent work. As such, the committee is presented with the most relevant and up-to-date information on which to make their recommendations.

### 20d. Why can't the advice or information this committee provides be obtained elsewhere?

The committee is necessary to provide the requisite transparency and credibility to the process. Also, the MVDP staff value the committee's broad experience in all fields of malaria vaccine development and rely on the committee members for assistance in planning program direction.

## 20e. Why is it necessary to close and/or partially closed committee meetings?

Portions of the meetings may be closed so that any issues pertaining to budget and procurement can be discussed openly.

#### 21. Remarks

**Designated Federal Officer** 

Susan Youll DFO

#### **Narrative Description**

# What are the most significant program outcomes associated with this committee?

	Checked if	
	Applies	
Improvements to health or safety		
Trust in government		
Major policy changes		
Advance in scientific research		
Effective grant making		
Improved service delivery		
Increased customer satisfaction		
Implementation of laws or regulatory		
requirements		
Other		

#### **Outcome Comments**

#### What are the cost savings associated with this committee?

	Checked if Applies
None	Y
Unable to Determine	
Under \$100,000	
\$100,000 - \$500,000	
\$500,001 - \$1,000,000	
\$1,000,001 - \$5,000,000	
\$5,000,001 - \$10,000,000	
Over \$10,000,000	
Cost Savings Other	

**Cost Savings Comments** 

What is the approximate <u>Number</u> of recommendations produced by this committee for the life of the committee?

**Number of Recommendations Comments** 

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Fully</u> implemented by the agency? %

% of Recommendations Fully Implemented Comments

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Partially</u> implemented by the agency?

% of Recommendations Partially Implemented Comments

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered? Yes No Not Applicable

#### Agency Feedback Comments

What other actions has the agency taken as a result of the committee's advice or recommendation?

	Checked if Applies
Reorganized Priorities	
Reallocated resources	
Issued new regulation	
Proposed legislation	

Approved grants or other payments
□

Other
□

Action Comments
□

Is the Committee engaged in the review of applications for grants?<br/>No
No

Grant Review Comments
□

How is access provided to the information for the Committee's documentation?<br/>Checked if Applies

Contact DFO
□

Online Agency Web Site
□

Online Committee Web Site
□

Online GSA FACA Web Site
□

Publications
□

Other
□

**Access Comments**